How Testosterone Enanthate Affects Transferrin Saturation

Transferrin saturation (TSAT) measures the percentage of transferrin (the main iron-transport protein in blood) that is loaded with iron. It reflects the balance between iron supply to the blood and iron consumption by tissues (primarily the bone marrow).

Testosterone affects transferrin saturation through competing mechanisms:

1. Hepcidin suppression increases iron supply: Androgens suppress hepcidin, the master iron-regulatory hormone. Lower hepcidin means more iron flows into the bloodstream from gut absorption and macrophage recycling. This increases the amount of iron loading onto transferrin, raising TSAT.

2. EPO-driven consumption increases iron demand: Testosterone stimulates erythropoietin production, increasing bone marrow demand for iron. The marrow pulls iron off transferrin for haemoglobin synthesis, which would lower TSAT.

3. Net effect depends on phase and context:

   • Early on TRT (first weeks to months): hepcidin suppression typically dominates, and TSAT may rise
   • Over time with sustained erythropoiesis: marrow consumption may catch up, stabilising or lowering TSAT
   • With phlebotomy: iron loss can exceed supply, dropping TSAT as stores are depleted
   • With hemochromatosis: hepcidin is already deficient, and testosterone-mediated suppression further increases absorption, potentially pushing TSAT above 60-80%

TSAT above 45% is the standard screening threshold for hemochromatosis. Testosterone-driven hepcidin suppression can push TSAT above this threshold even in men without hemochromatosis, making clinical context essential for interpretation.

Replacement doses (100-200 mg/week):

• TSAT may increase 5-15% from baseline in the first 3-6 months
• Most men stabilise with TSAT of 25-45%
• Men with pre-existing high TSAT or hemochromatosis may exceed 50%

Supraphysiological doses (300-600+ mg/week):

• Greater hepcidin suppression can push TSAT higher
• However, greater EPO-driven iron consumption may partially offset this
• Net effect is variable

With regular phlebotomy:

• TSAT typically drops as iron stores are depleted
• TSAT below 16% indicates iron-restricted erythropoiesis and is a signal to pause phlebotomy and supplement iron

Timing matters: TSAT fluctuates significantly through the day and with meals. Always test fasting, in the morning, and away from iron supplementation for consistent results.

Baseline: Include transferrin saturation as part of the pre-TRT iron panel. TSAT above 45% at baseline warrants HFE gene testing before starting testosterone.

Interpretation guidelines:

• Test fasting, morning blood draw
• Do not test within 24 hours of iron supplementation
• Interpret alongside ferritin (TSAT alone can be misleading due to diurnal variation)
• TSAT above 45% on TRT does not automatically mean hemochromatosis; repeat the test and correlate with ferritin

Follow-up: Every 6-12 months as part of the iron panel. More frequent if ferritin is declining or TSAT is trending toward extremes.

Decision thresholds:

• TSAT below 16%: Iron-restricted erythropoiesis. Pause phlebotomy, supplement iron.
• TSAT 20-45%: Normal range for most TRT patients
• TSAT above 45% with elevated ferritin: Investigate hemochromatosis (HFE testing)
• TSAT above 45% with normal or low ferritin: Likely an artifact of testosterone-driven hepcidin suppression. Monitor and retest.

If TSAT is low (below 20%) on TRT:

• Indicates iron supply is not keeping up with demand
• Check ferritin to confirm iron depletion
• If ferritin is also low: supplement iron, pause phlebotomy
• If ferritin is normal but TSAT is low: consider inflammation (CRP), which raises hepcidin and blocks iron release despite adequate stores

If TSAT is elevated (above 45%) on TRT:

• First: repeat fasting morning test to confirm (TSAT is notoriously variable)
• Check ferritin:
  • If ferritin is also elevated (above 300 ng/mL): strong indication for HFE gene testing
  • If ferritin is normal (30-150 ng/mL): likely testosterone-driven hepcidin suppression. Monitor every 3-6 months.
• If hemochromatosis is confirmed: therapeutic phlebotomy is first-line treatment, which also manages TRT-related polycythemia
• Avoid iron supplements and iron-fortified foods

If TSAT is critically high (above 60%):

• Urgent evaluation for hemochromatosis or liver disease
• TSAT above 60% increases the risk of non-transferrin-bound iron (NTBI), which is toxic to the liver, heart, and pancreas
• Do not attribute to testosterone alone at this level

Clinical pearl: TSAT is the single best screening test for hemochromatosis (better sensitivity than ferritin alone). If TRT pushes TSAT above 45% on two consecutive fasting tests, HFE testing is warranted even if the patient has no symptoms.